Targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide

Molecular Cancer Research

Volumn 8, Issue 2, 2010, Pages 135-144

  Du, Bing ^a   Han, Honghui ^a   Wang, Ziqiang ^a   Kuang, Lisha ^a   Wang, Lei ^a   Yu, Liping ^a   Wu, Miao ^a   Zhou, Zhongliang ^a   Qian, Min ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLGLYCYLLYSYLGLYCYLTHREONYLALANYLALANYLLEUCYLGLUTAMYL THREONYLTHREONYLPROLINE; ALANYLGLYCYLLYSYLGLYCYLTHREONYLPROLYLSERYLLEUCYLGLUTAMYL THREONYLTHREONYLPROLINE; ANTINEOPLASTIC AGENT; DOXORUBICIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER SIZE; CANCER SURVIVAL; CANCER TISSUE; CELL PROLIFERATION; CLONING; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTER; FLUORESCENCE MICROSCOPY; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER CANCER; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN BINDING; XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BACTERIOPHAGES; BINDING, COMPETITIVE; BIOLOGICAL ASSAY; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FLOW CYTOMETRY; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; PEPTIDE LIBRARY; PEPTIDES; PROTEIN BINDING; TRANSPLANTATION, HETEROLOGOUS;

MUS;

EID: 77249124505     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0339     Document Type: Article

References (45)

1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-41.
3. Forner A, Hessheimer AJ, Isabel RM, Bruix J. Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol 2006;60:89-98.
4. Tortora G, Daniele G. [New frontiers in cancer treatment]. Recenti Prog Med 2006;97:781-6.
5. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001;291:1304-51.
6. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921.
7. Qin LX, Tang ZY. Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol 2004;130:497-513.
8. Hassan ME, Azzazy WEH, Jr. Phage display technology: clinical applications and recent innovations. Clin Biochem 2002;2002:425-45.
9. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985;228: 1315-7.
10. Arap W, Kolonin MG, Trepel M, et al. Steps toward mapping the human vasculature by phage display. Nat Med 2002;8:121-7.
11. Trepel M, Arap W, Pasqualini R. In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr Opin Chem Biol 2002;6:399-404.
12. Lee TY, Lin CT, Kuo SY, Chang DK, Wu HC. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res 2007;67:10958-65.
13. Zitzmann S, Mier W, Schad A, et al. A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. Clin Cancer Res 2005;11:139-46.
14. Lo A, Lin CT, Wu HC. Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol Cancer Ther 2008;7:579-89.
15. Krumpe LR, Mori T. The use of phage-displayed peptide libraries to develop tumor-targeting drugs. Int J Pept Res Ther 2006;12:79-91.
16. Xu MY, Xu XH, Chen GZ, et al. Production of a human single-chain variable fragment antibody against esophageal carcinoma. World J Gastroenterol 2004;10:2619-23.
17. Fatehi AN, van den HR, Colenbrander B, et al. Expression of bone morphogenetic protein2 (BMP2), BMP4 and BMP receptors in the bovine ovary but absence of effects of BMP2 and BMP4 during IVM on bovine oocyte nuclear maturation and subsequent embryo development. Theriogenology 2005;63:872-89.
18. Kamizuru H, Kimura H, Yasukawa T, Tabata Y, Honda Y, Ogura Y. Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the rat. Invest Ophthalmol Vis Sci 2001;42:2664-72.
19. Rajarao GK, Nekhotiaeva N, Good L. The signal peptide NPFSD fused to ricin A chain enhances cell uptake and cytotoxicity in Candida albicans. Biochem Biophys Res Commun 2003;301:529-34.
20. Jain RK. The next frontier of molecular medicine: delivery of therapeutics. Nat Med 1998;4:655-7.
21. Braun K, Pipkorn R, Waldeck W. Development and characterization of drug delivery systems for targeting mammalian cells and tissues: a review. Curr Med Chem 2005;12:1841-58.
22. Zhu Z, Rockwell P, Lu D, et al. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res 1998;58:3209-14.
23. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Cilengitide targeting of α(v)β(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002;62:4263-72.
24. Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled α(v)β(3) integrin binding peptides in a nude mouse model. Cancer Res 2002;62:6146-51.
25. Ragin AD, Morgan RA, Chmielewski J. Cellular import mediated by nuclear localization signal peptide sequences. Chem Biol 2002;9: 943-8.
26. Friedler A, DeDecker BS, Freund SM, Blair C, Rudiger S, Fersht AR. Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for "mutant conformation". J Mol Biol 2004;336:187-96.
27. Friedler A, Hansson LO, Veprintsev DB, et al. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci U S A 2002;99:937-42.
28. Higgins LM, Lambkin I, Donnelly G, et al. In vivo phage display to identify M cell-targeting ligands. Pharm Res 2004;21:695-705.
29. Liu C, Bhattacharjee G, Boisvert W, Dilley R, Edgington T. In vivo interrogation of the molecular display of atherosclerotic lesion surfaces. Am J Pathol 2003;163:1859-71.
30. Ruoslahti E. Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol 2000;10:435-42.
31. Rafii S, Avecilla ST, Jin DK. Tumor vasculature address book: identification of stage-specific tumor vessel zip codes by phage display. Cancer Cell 2003;4:331-3.
32. Essler M, Ruoslahti E. Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc Natl Acad Sci U S A 2002;99:2252-7.
33. Watters JM, Telleman P, Junghans RP. An optimized method for cellbased phage display panning. Immunotechnology 1997;3:21-9.
34. Hajitou A, Pasqualini R, Arap W. Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med 2006;16:80-8.
35. Brock CS, Lee SM. Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer. Eur Respir J 2002;19:557-70.
36. Fu Z, Kitagawa Y, Shen R, et al. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate 2006;66:248-56.
37. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80.
38. Bockmann M, Drosten M, Putzer BM. Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma. J Gene Med 2005;7:179-88.
39. Salvatore G, Beers R, Margulies I, Kreitman RJ, Pastan I. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res 2002;8:995-1002.
40. White SJ, Nicklin SA, Buning H, et al. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation 2004;109:513-9.
41. Du B, Qian M, Zhou Z, et al. In vitro panning of a targeting peptide to hepatocarcinoma from a phage display peptide library. Biochem Biophys Res Commun 2006;342:956-62.
42. Leja J, Essaghir A, Essand M, et al. Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Mod Pathol 2009;22:261-72.
43. Yoshimoto M, Ogawa K, Washiyama K, et al. α(v)β(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide. Int J Cancer 2008;123:709-15.
44. Greish K, Sawa T, Fang J, Akaike T, Maeda H. SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumors. J Control Release 2004;97:219-30.
45. Berger DP, Winterhalter BR, Fiebig HH. The nude mouse in oncology research. Boca Raton (FL): CRC Press; 1991.